Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

Trial arms side by side.

One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.

ClassNone selected

No arms selected. Choose a drug, an arm, or a preset.

7 of 9 arms with a reported figure. Choose arms to narrow the chart.

Drug, trialPopulationDoseEstimandComparatorORR, %mPFS, monthsmOS, monthsHazard ratioOther
Vorasidenib 40 mgINDIGOgrade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery only (n = 168 vs 163)40 mgITTplaceboobjective response rate, extended follow-up: 20.8%, ASCO 2026, preliminarymedian PFS, vorasidenib: 27.7 months, NEJM 2023median PFS, placebo: 11.1 months, NEJM 2023median PFS, extended follow-up: 44.1 months, ASCO 2026, preliminaryn/rPFS hazard ratio vs placebo (BIRC): 0.39 HR, primary analysistime to next intervention hazard ratio: 0.26 HR, primary analysismedian time to next intervention, placebo: 17.8 months, primary analysis
Vorasidenib Phase 1 dosesVorasidenib Phase 1recurrent non-enhancing IDH-mutant glioma (n = 22)Phase 1 dosesSingle armn/robjective response rate: 18%, Phase 1median PFS: 36.8 months, Phase 1n/rn/rn/r
Safusidenib (AB-218, DS-1001) 250 mgJ201 Phase 2IDH1-mutant grade 2 glioma, Japan (n = 27 per company; registry n = 25)250 mgSingle armn/rconfirmed objective response rate: 51.9%, median follow-up 38.8 months36-month PFS rate: 79.1%, median follow-up 38.8 monthsn/rn/rn/r
Olutasidenib 150 mgOlutasidenib Phase 1/2 (glioma cohort)relapsed or refractory IDH1-mutant glioma (26 enrolled, 25 evaluable)150 mgSingle armn/robjective response rate: 8%, 2 of 25n/rn/rn/rdisease control rate: 48%, 12 of 25
Ivosidenib Phase 1 dosesIvosidenib Phase 1 (glioma)recurrent non-enhancing IDH1-mutant gliomaPhase 1 dosesSingle armn/rn/rmedian PFS: 13.6 months, 95% CI 9.2 to 33.2n/rn/rn/r
IDH1-VAC (IDH1 R132H Peptide Vaccine) not stated in sourceNOA-16newly diagnosed IDH1 R132H astrocytomanot stated in sourceSingle armn/rn/r3-year PFS rate: 63%n/rn/rvaccine-induced immune response: 93.3%, 28 of 30 evaluable
Olaparib 300 mgOLAGLIrecurrent IDH-mutant high-grade glioma (n = 35)300 mgSingle armn/rn/r6-month PFS rate: 31.4%, primary endpoint, target 50% not metmedian PFS: 2.05 monthsmedian OS: 15.9 monthsn/rn/r

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.